Organon & Co（OGN）近日宣布与日本制药巨头第一三共（Daiichi Sankyo）签署重要商业合作协议，获得其降胆固醇药物Nilemdo®在法国、丹麦、冰岛、瑞典、芬兰和挪威六个欧洲国家的独家商业化权利。此次合作将显著拓展Organon在欧洲心血管疾病治疗领域的产品组合，同时强化第一三共创新药物在全球市场的渗透力。
Nilemdo®作为新型降脂疗法，此前已在欧盟获批用于原发性高胆固醇血症或混合性血脂异常的治疗。通过此次协议，Organon将依托其成熟的欧洲分销网络，加速该药物在北欧和西欧地区的市场准入。双方未披露具体财务条款，但透露合作包含阶段性销售里程碑付款机制。
这一战略布局不仅彰显Organon对欧洲高价值医药市场的深耕决心，更凸显其通过外部合作快速扩充特色药品管线的商业模式。随着人口老龄化加剧，心血管药物需求持续增长，此次合作有望为双方带来可观的市场回报。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.